In the early studies with recombinant human erythropoietin (EPO) in hemodialysis patients, EPO was given intravenously at the end of dialysis. More recently the drug has also been used with continuous ambulatory peritoneal dialysis (CAPO) and before initiating dialysis. As regular intravenous (i.v.) administration is clearly impractical in such patients, alternative intraperitoneal (i.p.) and subcutaneous (s.c.) routes were considered and their pharmacokinetics studied. More recently, the issue of pain after s.c. injection has also attracted attention.
The currently available EPO preparations, epoetin alta (EPO alfa) and epoetin beta (EPO beta), are both synthesized in Chinese hamster ovary cells (CHO) by expression of a human erythropoietin clone. They have an identical amino acid structure and sequence but differ in oligosaccharide configuration, possibly due to differences in CHO cell phenotype or to the derivation from genomic DNA for EPO alfa and from complementary DNA for EPO beta (1) . EPO alta (Eprexw, Cilag, Switzerland and Epogen®, Amgen, California, USA) is available as a ready to use solution containing 2.5% human serum albumin. EPO beta (Recorrnonw, Boehringer-Mannheim, Germany and Epogin®, Chugai-Upjohn, Japan) comes as an albumin-free lyophilized powder for reconstitution with water for injection (Recormon®) and as vials containing 1 mg human serum albumin and 25 mg 0-mannitol to be reconstituted with isotonic sodium chloride solution (Epogin®).
The bioavailabillty of EPO administered intraperitoneally in dialysis fluid is about 3 to 8% (2) . Although this would suggest that it is not an economical mode of treatment, an effective clinical response has been reported with l.p. EPO (3) . Bioavailability is increased following injection into a dry peritoneal cavity (4). After s.c. injection bioavailability is 20 to 30% (2). The pharmacokinetic advantage of this route is the slow resorption. This results in a delayed serum peak level at about 18 hours that is maintained for several hours, so that detectable serum concentrations are still present after 4 days. By contrast, after i.v, administration a high unphysiologic peak serum concentration and a shorter half life of 4 to 12 hours result in concentrations returning to baseline within 2 to 3 days (2). In children, EPO is better absorbed but more readily cleared (5) . Furthermore, bioavailability is higher when injected into the thigh than in the upper arm or the abdomen (6) . Finally, some differences in the pharmacokinetics of epoetin alfa and beta result in a small but significantly greater absolute reticulocyte response after subcutaneous epoetin beta compared to EPO alta (7) .
Studies comparing dose response after i.v, or s.c. administration have shown that s.c. injection is equally effective at about 50% lower doses (8, 9) . Moreover, the rise in hematocrit (Hct) is 38% greater with the s.c. route for the same weekly dose of EPO (10) . The efficacy of i.v. EPO can be improved by more frequent injections (3 times/week vs 2/week) (8) .
With s.c. therapy, the maintenance dose is reported to be comparable in patients receiving 1 or 2 (11) and 2 or 3 (8) injections per week. A small saving in EPO dose, calculated to be 15-20%, is reported with daily administration compared to 3 times weekly (12) . However, it may prove no cheaper than 3 times per week as 7 injections weekly may offset the small saving in EPO dose. In a recent multicenter survey (10, 13) , efficacy correlated negatively with baseline hematocrit and administration frequency in HO as well as in CAPO patients. CAPO patients responded better than HO patients: the increase in Hct per weekly EPO dose was 60% higher compared to HO patients.
The pharmacokinetics after s.c. administration that allow lower doses may offer more than merely eco-nomic advantages. By avoiding unphysiologic peak serum levels s.c. administration may reduce doserelated side-effects. S.c. EPa in CAPO patients has caused few flu-like syndromes (14) ; and even few hypertension problems (15) than i.v. EPa in hemodialysed patients.
Although the s.c. route appears preferable, many clinicians continue to treat their hemodialysis patients intravenously because it is convenient to administer the drug into the extracorporeal circuit and because patients may complain of pain at the site of subcutaneous injection (14, (16) (17) (18) (19) (20) . Reports indicate that more than half of the patients experienced mild to very severe pain after the injection of EPa alfa (Eprex®, Cilag, Switzerland) into the abdomen (19) , the upper arm (17, 19) and the thigh (20) , whereas EPa beta (Recormon®, Boehringer-Mannheim, Germany) injection cause little or no pain in most patients (16, 17, 19, 20) . After administration into the upper arm, a high rate of swellings was observed with both preparations (19) . In these studies, the injected volume was 1 ml (17-19) or 0.5 to 1 ml (20) , except in one patient in our series who experienced the most severe pain after 1.5 ml s.c. EPa alfa (20) . In this regard it would be preferable to keep the volume to be injected as low as possible. In our experience, local pain tended to be more severe in a patient group formerly treated intravenously (20) . This possibly indicates the development of pain tolerance in patients who become accustomed to the s.c. route. Although EPa beta scored very well on the pain scale, treatment acceptance was less than 80% in subjects switched from i.v. to s.c. administration. By contrast, patients used to the s.c. route, had a treatment acceptance close to 100% for EPa beta. Refusal to switch from the i.v, to the s.c. route was about 50% for EPa alfa (20) . The Japanese EPa beta preparation (Epoqinw, Chugai, Japan) was also found to be less painful than Eprex®, although the difference between Eprex and Epogin® is less marked than between Eprex® and Recormon® (18) .
It has been suggested that the local pain after s.c. injection of EPa alfa results from additives such as albumin (16) (17) (18) . However, we demonstrated that the s.c. injection of human serum albumin at an equivalent concentration causes no pain (20) . We therefore suspect that additives other than albumin, either the EPa itself or some additive with anaesthetic properties 2 in the EPa beta preparation, may be responsible for the differences between the two brands in causing local pain. Granolleras et al. (19) suspect polysorbatum 20 (Tween 20®) to have a local anaesthetic effect that could contribute to this observed effect.
In conclusion, s.c. epoetin treatment may have more than only economic advantages. In our opinion it should be the preferred route not only in CAPO and pre-dialysis patients but also in hemodialysis patients. Local pain at the injection site, however, may compromise the acceptance of this mode of treatment in hemodialysis patients, especially if they are used to being treated intravenously. Therefore, the s.c. route should be chosen from the beginning of the treatment. The conditioning of the EPa is important in respect to the local pain reactions. EPa per se (due to differences in glycosylation), or additives other than albumin, are probably responsible for the difference in local pain. Further study is needed to elucidate this phenomenon.
